Aging
Navigate
Submit an Article
Research Paper|Volume 13, Issue 2|pp 1620—1632

Lung adenocarcinoma patients have higher risk of SARS-CoV-2 infection

Long Chen1, Yue Liu1, Jiamin Wu3, Chao Deng2, Jianjun Tan2, Huawen Liu2, Li Zhong1
  • 1Bioengineering Institute of Chongqing University, Chongqing, China
  • 2Three Gorges Central Hospital, Wanzhou, Chongqing, China
  • 3Chongqing Mix Biotechnology Co., Ltb, Chongqing, China
Received: June 11, 2020Accepted: July 30, 2020Published: January 10, 2021
https://doi.org/10.18632/aging.202375

Copyright: © 2021 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Both lung adenocarcinoma and coronavirus disease 2019 would cause pulmonary inflammation. Angiotensin-converting enzyme 2, the functional receptor of SARS-CoV-2, also plays a key role in lung adenocarcinoma. To study the risk of SARS-CoV-2 infection in lung adenocarcinoma patients, mRNA and microRNA profiles were obtained from The Cancer Genome Atlas and Gene Expression Omnibus followed by bioinformatics analysis. A network which regards angiotensin-converting enzyme 2 as the center was structured. In addition, via immunological analysis to explore the essential mechanism of SARS-CoV-2 susceptibility in lung adenocarcinoma. Compared with normal tissue, angiotensin-converting enzyme 2 was increased in lung adenocarcinoma patients. Furthermore, a total of 7 correlated differently expressed mRNAs (ACE2, CXCL9, MMP12, IL6, AZU1, FCN3, HYAL1 and IRAK3) and 5 correlated differently expressed microRNAs (miR-125b-5p, miR-9-5p, miR-130b-5p, miR-381-3p and miR-421) were screened. Interestingly, the most frequent toll-like receptor signaling pathway was enriched by mRNA (interlukin 6) and miRNA (miR-125b-5p) sets simultaneously. In conclusion, it was assumed that miR-125b-5p-ACE2-IL6 axis could alter the risk of SARS-CoV-2 infection in lung adenocarcinoma patients.